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Abstract: Despite tremendous efforts over the course of many years, the quest for an 
effective HIV vaccine by the classical method of active immunization remains largely 
elusive. However, two recent studies in mice and macaques have now demonstrated a new 
strategy designated as Vectored ImmunoProphylaxis (VIP), which involves passive 
immunization by viral vector-mediated delivery of genes encoding broadly neutralizing 
antibodies (bnAbs) for in vivo expression. Robust protection against virus infection was 
observed in preclinical settings when animals were given VIP to express monoclonal 
neutralizing antibodies. This unorthodox approach raises new promise for combating the 
ongoing global HIV pandemic. In this article, we survey the status of antibody gene 
transfer, review the revolutionary progress on isolation of extremely bnAbs, detail VIP 
experiments against HIV and its related virus conduced in humanized mice and macaque 
monkeys, and discuss the pros and cons of VIP and its opportunities and challenges 
towards clinical applications to control HIV/AIDS endemics.  
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1. Introduction 
Since the emergence of Acquired Immune Deficiency Syndrome (AIDS) more than 30 years ago, 
over 25 million people have died of AIDS, and about 34.2 million have been infected with human 
immunodeficiency virus (HIV), the virus that causes AIDS [1,2]. The disease has a disproportionately 
larger impact in underdeveloped parts of the world, where AIDS has devastated whole countries, 
especially in Africa, killing both adults and children and dramatically decreasing life expectancy and 
economic growth. Although the development of drug-based anti-retroviral therapy (ART) has slowed, 
or even halted, the progression of AIDS, it cannot cure the disease; for most cases, HIV-infected 
individuals left untreated do not survive. This lifelong dependence on drug therapy raises significant 
concerns on the sustainability and affordability of ART and presents daunting global economic and 
health problems [2].  
It is widely agreed that the most effective method to stop or slow the AIDS epidemic is a safe and 
efficacious vaccine [3–5]. Unfortunately, despite almost 30 years of intense scientific investigations, 
no effective HIV/AIDS vaccine is approaching licensure. To account for such failure, scientists have 
pointed to the unique properties that HIV has evolved to evade immune recognition [6,7].  
Accumulating evidence from other viruses and HIV-related animal model studies suggests the need for 
vaccine-elicited neutralizing antibodies (nAbs) as the most effective protection against HIV infection 
[8–16]. However, HIV is an enveloped retrovirus that presents challenges for conventional nAb-based 
vaccine strategies. The virus mutates rapidly to change its surface structure, utilizes host-derived 
nonimmunogenic glycans to mask its exposed surface, and hides its conserved and potentially 
vulnerable regions, such as the CD4 binding site in the interfaces of oligomeric proteins [6,17]. 
Although 20% of chronically HIV-infected individuals generated nAbs and 2%–4% of them have 
broadly neutralizing antibodies (bnAbs) capable of neutralizing most tested HIV strains [18], these 
antibodies are only produced after months to years of virus infection [1]. The challenge lies in 
identifying vaccine preparations and delivery methods to elicit antibodies, preferably nAbs, to protect 
humans from infection upon HIV exposure.  
As an alternative to traditional vaccine methods, recent studies in mice [19] and monkeys [20] 
demonstrated a gene therapy approach for generating vaccine-like protection by delivering genes 
encoding nAbs into nonhematopoietic tissues, such as muscles [21–23]. This novel strategy is called 
Vectored ImmunoProphylaxis (VIP) (Figure 1). The advantage of this approach lies in the direct 
provision of nAbs through transgene expression in host cells, bypassing the reliance on the natural 
immune system for mounting desired humoral immune responses. VIP extends the application of 
monoclonal antibodies (mAbs) from passive immunization to a new form of gene therapy that is based 
on transfer of antibody genes and their subsequent expression in host tissues. In this article, we will 
review antibody-based gene transfer and the recent development of HIV-specific bnAbs, followed by a 
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discussion of the pros and cons of VIP and its opportunities and challenges towards clinical 
applications to control HIV/AIDS endemics.  
Figure 1. Schematic representation of the Adeno-associated virus-based vector (AAV)-
based Vectored ImmunoProphylaxis (VIP) approach against human immunodeficiency 
virus (HIV).  
 
2. Antibody Gene Transfer 
Since 1986, the US Food and Drug Administration (FDA) has so far approved nearly 30 monoclonal 
antibodies (mAbs) as therapeutic drugs for treating patients with cancer and with autoimmune, 
inflammatory and infectious diseases [24,25]. Many more promising mAbs are in preclinical and 
clinical development. Thus, therapeutic antibodies have become the fastest growing class of 
therapeutic molecules in the pharmaceutical industry [26–28]. Antibody therapies generally involve 
high doses over a long period of time, thereby requiring large amounts of clinical-grade reagents for 
treating one patient, and yet mAbs are among the most complicated and expensive pharmaceutical 
products to manufacture [29–33]. Therefore, development of robust manufacturing processes to 
produce individual mAbs with high capacity and yield remains a bottleneck for rapid delivery of 
therapeutic benefits to patients. To overcome this barrier, an alternative approach would involve the 
body itself in completing antibody production. Indeed, a myriad of preclinical studies have 
demonstrated that antibody production in vivo after gene transfer is feasible and that it can potentially 
accelerate the translation of therapeutic mAbs from bench to bedside.  
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2.1. Delivery Methods 
A key step in antibody gene transfer is the identification of appropriate delivery vectors to 
efficiently deliver antibody genes into host tissues for in vivo expression. Nonviral delivery by 
electroporation of naked DNA to muscle cells has been explored for in vivo transfer of genes encoding 
mAbs [34–37]. Plasma antibody concentrations of 0.4–1.5 μg/mL were observed in mice and sheep for 
a period of 6–7 months. This confirmed that skeletal muscle cells possess the cellular factors required 
to synthesize antibodies and that highly vascularized muscle can transport produced antibodies into the 
systemic circulation. Although nonviral vectors are easy to produce and do not induce vector-specific 
immune responses [38], the transfer efficiency is low, yielding only minimal production of antibodies, 
which may not be practical for therapy.  
Based on their higher transduction efficiency, various viral vectors have been tested for in vivo 
antibody gene transfer. Intravenous administration of adenoviral vectors (Ads) to mice showed  
long-term average antibody concentrations in serum ranging from ~0.02 μg/mL to >40 μg/mL, with 
peak concentrations as high as 1 mg/mL [39–41]. These experiments used the most well-studied vector 
derived from serotype 5 of human adenovirus (Ad5). High transgene expression usually occurred in 
liver, lung and spleen for this vector after tail vein injection in mice. Antibody production could be 
detected as early as day 1 and peaked at days 3–6 post-administration, after which expression 
decreased rather quickly [41]. In addition to its transient expression, which is not suited for antibody 
therapy requiring sustained delivery, clinical utilization of Ads is hindered by the inflammatory and 
immune response they evoked after in vivo administration [38,42,43]. Many Ad-based gene therapy 
studies concluded that this vector system might be best suited for applications that need only transient 
expression and that immune stimulation is desired, such as genetic vaccination and cancer gene 
therapy [44].  
Adeno-associated virus-based vectors (AAVs), while not integrated into the genome, can transduce 
nonreplicating and long-lived cells in vivo, and the resulting expression can persist for months to years 
in their associated tissues [38,44]. This also indicates that anti-vector immunity induced by AAVs is  
at a manageable level [45] so that vector-modified cells can survive from the immune system for a 
long period of time. Thus, various serotypes of AAVs have become the most appealing vectors for  
in vivo gene therapy [46], and many of them have shown promising results in early-phase clinical  
trials [47–58]. The challenge for AAVs as delivery vehicles is their limited packaging capacity. 
Therefore, since AAVs cannot accommodate the conventional antibody expression cassette with heavy 
and light chains under two separate promoters or with heavy and light chains under one promoter but 
linked by a DNA sequence for internal ribosome entry site (IRES). Clark and coworkers constructed a 
dual-promoter AAV2 for expression of IgG1b12 antibody [59]. Although the vector could be 
produced, its titer was compromised owing to the large DNA insert that reached the packaging limit of 
AAV2. As a compensatory method, the same group had to design an immunoadhesin form of 
antibody-like molecules, which has shorter sequences, for efficient packaging and production of high 
quality AAVs [20]. However, this packaging barrier has now been overcome by an elegant approach, 
in which a foot-and-mouth-disease virus (FMDV)-derived 2A self-processing sequence (F2A,  
only 72 base pairs long) is engineered with a furin cleavage site. Once placed between heavy and light 
chains, the efficient expression of antibodies by AAVs is enabled from a single reading frame driven 
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by one promoter [60]. The in vivo administration of AAV8 (4 × 1011 genome copies (gc)) with this 
FMDV 2A configuration through the hepatic portal vein led to average serum antibody of ~1 mg/mL 
for 4 months with peak concentration as high as >8 mg/mL. This work inspired many more studies 
with various serotypes of AAV administered by the intravenous [61], intranasal [62], intravitreal [63], 
intrapleural [64] or intramuscular [19] routes for in vivo antibody expression. These studies 
consistently showed high titer antibody production for a long period of time. Thus, it seems that AAVs 
are the most favorable delivery vectors to achieve durable and efficient in vivo expression of 
antibodies. It should be noted that AAV-mediated antibody expression usually takes two weeks in 
order to reach a significant level [65], which prevents its application in situations that require 
immediate antibody delivery. In light of different kinetics of antibody expression mediated by Ads 
(rapid, but short; 1 day to 4 weeks) and AAVs (slower, but lasting, from two weeks to years), Boyer 
and coworkers demonstrated that co-administration of Ad and AAV vectors effectively leads to both 
rapid and sustained delivery of antibodies in vivo [65].  
2.2. Diseases Targeted by Antibody Gene Transfer 
Passive immunization by therapeutic mAbs has already provided therapeutic benefits for cancer 
patients [25]. Following this success, antibody gene transfer was tested in various preclinical tumor 
models [66,67]. Based on their pioneering strategy of using 2A to link antibody heavy and light chains, 
Jooss and coworkers reported substantially retarded tumor growth after intravenous injection of AAV8 
encoding anti-VEGFR2 antibody in both mouse melanoma and human glioma models [60]. Qian and 
coworkers evaluated the Ad5-mediated intravenous delivery of trastuzumab and found that such 
treatment could lead to significant elimination of ovarian cancer in mice [40]. The same group also 
injected Ad5 vectors encoding the Rituxan version of anti-CD20 antibody and observed >40 μg/mL 
antibody production in serum, which enabled a complete elimination of transplanted B-cell lymphoma 
in nude mice [68]. In an A431 xenograft tumor model, Hermiston and coworkers were able to show 
significant inhibition of tumor growth when the anti-EGFR antibody-expressing AAV1 was 
administered intramuscularly in both prophylactic and therapeutic settings [69]. When a lentiviral 
vector (LV) was employed to deliver anti-Met antibody via either intravenous or intratumoral route, 
Comoglio and coworkers reported substantial tumor inhibition in a human colorectal carcinoma 
xenograft model. Using a similar LV vector, Zheng and coworkers showed that the vector-mediated 
delivery of anti-DR5 antibody via intramuscular administration prolonged the lifespan of mice 
inoculated with orthotopic human lung tumor cells [70]. Thus, in addition to Ad and AAV vectors, 
these two studies also suggest that the LV system can be exploited for viral vector-mediated delivery 
of antibodies in vivo as well.  
The efficacy of antibody gene transfer has also been evaluated in infectious diseases. In addition to 
HIV, which is discussed later, genetic delivery of the antibody has been used to prevent and/or treat 
infections induced by respiratory syncytial virus (RSV), the bacteria Yersinia pestis and anthrax, and 
the influenza virus. Worgall and coworkers constructed Ad5 and non-human primate serotype rh.10 
AAV (AAVrh.10) vectors encoding palivizumab, an anti-RSV antibody that has been clinically 
approved to prevent RSV infection in high-risk populations [71–73], and tested their ability to prevent 
RSV infection in mice [64]. While the intravenous injection of Ad5 could reduce RSV infection by at 
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least 5.4-fold, the intrapleural injection of AAVrh.10 was superior, being able to ameliorate infection 
with 10.6~14.3-fold lower RSV titer. In a lethal Yersinia pestis challenge in mice, Boyer and coworkers 
were able to protect 80% of animals from infection after administration of Ad5 encoding antibody 
against the V antigen of Yersinia pestis [41]. In an anthrax toxin challenge experiment in mice, the 
same research team demonstrated a dual-component delivery method by co-administration of Ad5 and 
AAVrh.10 vectors to afford both immediate (by Ad5) and durable (by AAVrh.10) protection [65], 
which can be important for applications against biowarfare/bioterrorism agents [74]. Chiba and 
coworkers evaluated an electroporation-based delivery of naked DNA encoding an anti-hemagglutinin 
antibody and found that the produced antibodies were sufficient to protect mice from lethal influenza 
virus challenge, despite its relatively transient expression [37]. Subsequently, Baltimore and coworkers 
demonstrated that intramuscular administration of AAV8 encoding broadly neutralizing antibodies 
could protect mice from infection by diverse strains of H1N1 influenza [75]. Additionally, Wilson and 
coworkers showed that intranasal delivery of AAV9 harboring a different broadly neutralizing 
antibody could elicit broad protection against clinical isolates of H5N1 and H1N1 influenza viruses in 
mice and ferrets [62].  
To address cocaine addiction, Crystal and coworkers intravenously administered AAVrh.10 
expressing an anti-cocaine antibody into mice and found that the produced antibody was sufficient to 
sequester intravenously administered cocaine in the blood [76]. Consequently, treated animals were 
completely resistant to the cocaine. When an anti-nicotine antibody was constructed into AAVrh.10, 
the same team demonstrated that vector injection yielded nicotine-specific antibodies capable of 
shielding the brain from systemically administered nicotine, resulting in the absence of physiologic 
effects of nicotine in the treated mice [61]. These studies expanded the applications of antibody gene 
transfer from cancer and infectious diseases to addiction disorders, demonstrating the broad utility of 
this method.  
3. Discovery of HIV-Specific Neutralizing Antibodies  
For all available human and veterinary vaccines against infectious viruses, the serum level of nAbs 
correlates closely with the degree of protection [8]. The mechanism of neutralization by nAbs lies in 
either blocking the interaction between viral envelopes with their receptors or inhibiting viruses for 
their further transport to cytoplasm [77,78]. Mounting evidence suggests that antibody-based 
neutralization is also vital for HIV protection [9–16], although antibody-dependent cytotoxicity 
(ADCC) and antibody-dependent cell-mediated virus inhibition (ADCVI) may play roles in curbing 
viral load through controlling the later phase of virus replication [79]. Because HIV possesses many 
features to evade humoral immune responses, many difficulties have arisen in previous years in 
isolating bnAbs. Before 2009, we had only a limited number of so-called “first-generation bnAbs 
against HIV” [6,78,80]. However, since 2009, breakthroughs have been made, and a large panel of 
“second-generation bnAbs against HIV” has been identified. These bnAbs have greater neutralization 
potency and breadth [78,81], and they are all excellent resources for antibody gene transfer to  
target HIV.  
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3.1. First-Generation bnAbs against HIV 
The first broadly neutralizing human Ab against HIV is b12, which was isolated from a clade  
B-infected patient through phage screening of libraries of heavy and light chains [82]. Because of this 
isolation method, it is unknown whether or not this is a naturally occurring anti-HIV antibody. It was 
shown that b12 could recognize the CD4 binding site (CD4bs) on the gp120 surface of the HIV 
envelope (Env) [83] and could neutralize nearly 50% of clade B viral strains and 30% of non-clade B 
strains [84,85]. Another conserved vulnerable site on the gp120 of the HIV Env is the oligomeric 
glycan structure on the carbohydrate-masked surface of gp120. One bnAb, 2G12, was determined to 
bind to this glycan epitope and could neutralize many clade B-derived viral strains [86,87]. Once Env 
binds its receptor CD4, it triggers conformation changes to form and display a CD4-induced (CD4i) 
epitope, making it possible to develop HIV-specific mAbs [88]. Although this CD4i epitope is highly 
conserved among different clades, isolated mAbs, such as 17b, have only weak neutralization 
reactivity, and their potency can only be boosted if low concentrations of soluble CD4 (CD4s) are 
added or the Fab form of 17b is used in the neutralization assay [89]. In addition, one region on the 
gp41 of the HIV Env, called the membrane proximal external region (MPER), has been demonstrated 
as a good target for HIV-specific nAbs. 2F5 and 4E10 are the two most studied bnAbs that bind both 
the gp41 MPER and its nearby lipids [90,91]. One of them, 4E10, displays an impressive breadth of 
neutralization across several clades, although it only has weak to modest potency [92]. Thus, in spite 
of many years of study (from 1994 to 2008), only a handful of bnAbs (b12, 2G12, 2F5, 4E10) have 
thus far been identified as first-generation HIV-specific nAbs able to recognize three defined 
neutralization epitopes: CD4bs, glycan domain, and MPER [93].  
3.2. Second-Generation bnAbs against HIV 
Two seminal papers published in 2009 set a new course for discovery of the newer generation 
bnAbs against HIV [94,95]. To combine the cell sorting of gp140-binding B cells and single-cell 
antibody cloning, Nussenzweig and coworkers cloned over 500 mAbs to reveal that multiple 
antibodies targeting a range of Env epitopes contribute to the broad neutralizing serological activity of 
elite neutralizer in patients infected with HIV [94]. Concurrently, Burton and coworkers utilized a 
clonal B cell culture to screen over 30,000 activated memory B cells from a clade-A-infected African 
donor and identified two potent bnAbs, PG9 and PG16 [95], that target the V1/V2 loops of the  
gp120 [96]. Soon after, HJ16, a bnAb targeting CD4bs, was identified and is capable of neutralizing 
40% of viral isolates [97]. Subsequently, the design of antigenically resurfaced glycoproteins with 
exposed CD4bs led to more successful isolation of CD4bs-directed bnAbs [98]. After screening of 
several sera, sorting and single-cell cloning were performed on B cells from a donor with neutralizing 
reactivity. The isolated bnAb, VRC01 [98], could bind to CD4bs [99] and neutralize over 90% of 
tested HIV strains [98,100]. Building upon their previous work [95], Burton and coworkers screened 
memory B cells from four elite neutralizers and identified several glycan-dependent bnAbs, designated 
PGT121-PGT145 [101], some of which can penetrate the glycan shield and recognize an epitope in the 
vicinity of the V3 loop region, as well as two conserved glycans on gp120 [102]. Further studies 
isolated substantially more CD4bs-directed bnAbs and improved our understanding of the various 
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mechanisms used by these bnAbs to target HIV through this CD4bs [103,104]. A structural study of 
one of these bnAbs, NIH45-46, revealed a unique binding mode contributing to the increased 
interaction between the antibody and gp120, and a single amino acid substitution at this key binding 
area resulted in a variant, NIH-45-46G54W, with markedly enhanced breadth and potency [105]. More 
rational designs of this variant yielded a mutant, 45-46m2, which has greater breadth, and another 
mutant, 45-46m7, is capable of targeting a common HIV escape pathway [106]. Substantial advances 
were also made on MPER-specific antibodies, and an example of such newly identified bnAb, 10E8, 
could neutralize ~98% of tested virus strains, while at the same time having few of the shortcomings 
exhibited by previous bnAbs (e.g., 4E10 and 2F5) in this category, such as lipid binding and 
autoreactivity [107]. Kwong and coworkers have recently provided the most updated and 
comprehensive list of these HIV-specific bnAbs by clustering them into key recognition epitopes: 
CD4bs, V1/V2 loop, glycan-V3 site, and MPER [81]. The discovery of these bnAbs is not only 
transforming our understanding of humoral immune responses against HIV and facilitating the design 
of immunogens to elicit these antibodies, but it is also enabling researchers to test anti-HIV strategies 
that depend on passive immunization delivered by antibodies or antibody-encoded genes.  
4. Vectored Immunoprophylaxis for HIV by Antibody Gene Transfer  
Despite the tremendous success in identifying and characterizing bnAbs against HIV, a formidable 
challenge remains in designing appropriate forms of immunogens to elicit these antibodies through 
vaccination [3,78,108]. Passive immunization by antibody infusion showed promising results for HIV 
protection in macaque monkeys, but this type of long-term repeated treatment is too expensive, making 
it impractical for broad implementation in humans. Thus, vectored immunoprophylaxis (VIP), which 
involves a single injection of AAVs for in vivo delivery of genes encoding bnAbs, is an attractive 
alternative and enables continuous and sustained delivery of antibodies to prevent HIV infection.  
Two recent studies in animal models have demonstrated that VIP against HIV is feasible [19,20], 
paving the way for further clinical testing in humans.  
4.1. VIP against HIV in Mice  
To test VIP against HIV in mice, Baltimore and coworkers at the California Institute of Technology 
constructed AAV8 vectors encoding the full-length of one of bnAbs (b12, 2G12, 4E10, 2F5 and 
VRC01) [19]. In a pilot test, it was found that a single injection of AAV8 could achieve peak antibody 
production in serum at week 6. The expression decreased by 2- to 3-fold in the following weeks, but 
was then stably maintained for the duration of the study (64 weeks). Although the long-term 
expression was encouraging, the 4E10 antibody titer in serum is modest (~5 μg/mL) and therefore 
might not be sufficient for HIV protection. A series of optimizations were carried out to develop an 
improved antibody expression configuration in muscles. After testing several promoters, the authors 
created a new hybrid promoter, designated CASI, which combined the enhancer of the cytomegalovirus 
immediate early promoter (CMV), the β-actin promoter, and the enhancer of ubiquitin C (UBC) 
promoter flanked by a splicing donor and acceptor. In vivo expression analysis confirmed that CASI 
performed better than the conventional promoters tested. Incorporation of the woodchuck hepatitis virus 
posttranslational regulatory element (WPRE) [109] improved in vivo expression of luciferase nearly 
Viruses 2014, 6 436 
 
 
10-fold. The authors also optimized the configuration of the antibody transgene by codon-optimization 
of F2A, replacing the endogenous signal sequences with codon-optimized sequences derived from 
human growth hormone and removing the potential of inappropriate splicing sequences [110]. The final 
optimized AAV8 vector could mediate in vivo delivery of antibody b12 at a level that was 100-fold 
higher than that of non-optimized vector after a single injection of the gastrocnemius muscle [19].  
With the optimal vector in hand, the authors administered immunodeficient mice (NOD/SCID/γc 
strain, or NSG) with bnAb-encoded AAV8. When stable antibody production was reached (6 weeks), 
NSG mice were transplanted with human peripheral blood mononuclear cells (PBMCs).  
After engraftment for 2 weeks, mice were challenged with intravenous injection of the NL4-3 strain of  
HIV and monitored by the extent of CD4 depletion and the level of HIV p24 in tissues. Among the 
first-generation bnAbs, b12 (over 100 μg/mL) was the only antibody that afforded full protection, 
whereas 2G12 (~250 μg/mL), 4E10 (~25 μg/mL), and 2F5 (~25 μg/mL) yielded partial protection.  
In fact, AAV8-mediated expression of b12 was so potent that it could protect against HIV challenge at 
doses (125 ng) 100-fold higher than necessary to deplete CD4 T cells in control animals without b12 
expression. The authors also tested the delivery of a second-generation bnAb, VRC01, by AAV8 in the 
same animal model and compared its potency with b12. Although their expression was similar, VRC01 
could provide full protection against HIV challenge (10 ng) at a titer of 8.3 μg/mL, while a higher titer 
of b12 (34 μg/mL) was needed for equal protection, demonstrating in vivo that VRC01 is a superior 
antibody for AAV-mediated gene transfer to fight against HIV.  
Since the publication of this work, the Baltimore team has performed more experiments, and some 
of the most recent results were presented in a satellite symposium at the AIDS Vaccine 2012 
Conference [23]. Most human infections by HIV are through the mucosal surface; consequently, HIV 
needs to transport across many mucosal barriers for a successful infection [111]. New studies indicated 
that initial infection usually involves only one or a handful of founder viruses [112–114].  
Baltimore and colleagues performed VIP to mice to express b12 or VRC01, followed by intravenous 
HIV challenge with the REJO.c transmitted founder strain. It was observed that VRC01, but not b12, 
could provide substantial protection. This study not only confirms the superiority of VRC01, but also 
demonstrates that (1) founder viruses are not resistant to neutralization and (2) the newer generation of 
bnAbs can neutralize them in vivo. In order to model HIV transmission more closely to humans, the 
Baltimore group adapted a humanized BLT (bone marrow-liver-thymic chimeras) mouse system for 
VIP testing, in which a low dose, intravaginal challenge of HIV could be implemented. The BLT mice 
were highly resistant to the intravaginal challenge of a laboratory HIV strain, JR-CSF, after mice were 
given VIP to express VRC01 or an engineered, more potent VRC01-like antibody, VRC07G54W. 
Despite 15 repetitive exposures to the virus, 5 out of 8 VRC01-expressing mice and 12 out of 12 
VRC07G54W-expressing mice had no detectable level of HIV. For the two infected mice, the infection 
occurred at a much later phase of the repetitive challenge. More striking results were observed when 
the REJO.c transmitted founder strain was used to intravaginally infect mice given VIP to express 
VRC07G54W. All mice were protected with no detectable viral load by a PCR-based viral load assay. 
This series of experiments on BLT mice demonstrate that VIP can afford protection from mucosal HIV 
transmission and that VIP can allow for the delivery of not only natural antibodies, but also engineered 
antibodies, such as VRC07G54W. 
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4.2. VIP against SIV in Macaques 
Prior to work by the Baltimore team, Johnson and coworkers at the Children’s Hospital of 
Philadelphia had demonstrated the concept of VIP against simian immunodeficiency virus (SIV),  
an equivalent of HIV in humans, in macaque monkeys [20]. Without the optimal vector that the 
Baltimore team created, the Johnson team used the self-complementary AAV (scAAV) vectors with 
double-stranded genomes for better protein expression in vivo [115]. However, the tradeoff of scAAV 
is the reduced coding capacity for transgenes, making it impossible to carry the full-length of antibody 
genes. Thus, a designer molecule, called immunoadhesin, which has a shorter sequence than a full 
antibody, was chosen as an antibody-like protein in the study [20]. The designed anti-SIV 
immunoadhesin was composed of a single chain antibody (scFv) fused with an Fc portion of 
immunoglobulin constant domains. The study focused on two immunoadhesins, 4L6 and 5L7, along 
with an immunoadhesin (N4) that scFv was replaced with the binding domain of rhesus CD4.  
Each cohort of three monkeys was administered intramuscularly with either the serotype 1 of 
scAAV (scAAV1) for delivery of 4L6 and 5L7 or the serotype 1 of conventional single-stranded AAV 
(AAV1) at a dose of 2 × 1013 gc. The monkeys given VIP to express 4L6 exhibited impressive antibody 
production, which reached 100–190 μg/mL in 4 weeks post-vector injection, peaked in 4–6 months, 
and was maintained above 200 μg/mL thereafter. A great variation was seen in the 5L7 cohort, in 
which two monkeys had serum immunoadhesin of 40 μg/mL and 175 μg/mL at week 4 post-vector 
injection, while one monkey had 50 μg/mL immunoadhesin at 2 weeks, but lost its expression at week 
4 post-vector injection. The N4 cohort had much lower serum concentration of immunoadhesin, 
presumably from the lower vector-mediated expression by the single-stranded AAV1. All monkeys 
were challenged intravenously with SIV at week 4 post-vector injection. Remarkably, complete 
protection was seen in the entire 4L6 cohort, one monkey in the 5L7 cohort, and two monkeys in the 
N4 cohort. Further analysis revealed that the loss of 5L7 expression by one monkey was caused by the 
generation of immunoadhesin-specific antibody responses, which might have facilitated the clearance 
of transgene-expressing cells. These transgene-specific antibody responses were also detected in two 
other monkeys, one from the 5L7 cohort and one from the N4 cohort, albeit at a much lower level.  
The analysis of correlation of protection revealed that VIP protected only monkeys without detectable 
antibody responses against immunoadhesin. Nevertheless, the study by the Johnson team shows that 
VIP can provide robust protection against virus infection if immune responses against transgenes are 
appropriately controlled. It also highlights the superiority of natural antibody architecture, which should 
have lower immune responses as compared to non-self designer proteins, such as immunoadhesin.  
In the same satellite symposium at the AIDS Vaccine 2012 Conference, Dr. Johnson explained  
how his work had progressed since his last publication. He showed that the monkeys given VIP  
to express 4L6 immunoadhesin were able to maintain stable expression with serum concentration  
of ~20 μg/mL for over 5 years. This result is consistent with another previous study, in which 
intramuscular injection of AAV1 could maintain the expression of erythropoietin protein in monkeys 
for longer than 6 years [116]. This is exciting news because it means that long-term protection by VIP 
is possible in primates. Johnson also shared the result on comparing the neutralization activity of the 
full antibody vs. immunoadhesin forms of PG9. The full antibody architecture had neutralization 
potency that was 10-fold greater than that of immunoadhesin, which corroborates a previous report in a 
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similar study [117]. Because of the potency and immunogenicity, Dr. Johnson concluded in the 
meeting that the natural antibody architecture is preferred for future VIP testing in humans [23].  
5. Concluding Remarks  
Given that the quest for an effective vaccine through active immunization remains elusive, 
unorthodox approaches, such as VIP by antibody gene transfer, could raise new hopes in combating 
the ongoing global HIV pandemic. The studies exploring VIP as a novel modality of HIV prophylaxis 
in mice and macaques show encouraging results. Since the concept has been demonstrated and the 
preclinical experiments have been completed, the next hurdle is to evaluate such approach in humans. 
Indeed, two separate phase I trials are in the planning stage to test VIP delivered by intramuscular 
administration of AAVs encoding antibodies [23]. The trial led by Dr. Johnson and his colleagues is to 
use AAV1 for the delivery of the PG9 antibody into high-risk, seronegative volunteers.  
Discussions with the US FDA for the trial plan have been completed, and the clinical-grade vector has 
been manufactured. The trial is expected to be launched at the end of 2013 or in early 2014.  
In collaboration with Vaccine Research Center and the U.S. National Institutes of Health, the 
Baltimore team is planning a clinical trial to test VIP by AAV8-mediated delivery of the VRC01 
antibody via muscle injection to volunteers receiving treatment with ART.  
As we anxiously await the outcomes of these two trials, we should also recognize that several 
barriers lie ahead. First, we do not know how preclinical results in mice and macaques will be 
translated to humans. Although macaques may be the best animals to model HIV, they can be infected 
only by SIV and SHIV (chimeric simian/human immunodeficiency virus) [118–120], not HIV directly. 
Thus, it is unclear how the result of the model virus-based challenge experiment conducted in 
macaques given VIP to express HIV-specific bnAbs can be related to the true HIV control in humans. 
It seems that human trial remains the best means to determine successful VIP protocols, such as doses, 
sites of muscle injection, and serotypes of AAVs. Second, since VIP is a form of AAV-based gene 
therapy, it is subject to all the safety issues involved with this type of gene therapy, such as the 
immunogenicity of AAV vectors [45] and AAV-mediated insertional mutagenesis [121]. This becomes 
even more important when one considers that the intention of VIP is to provide prophylaxis for healthy 
individuals. Encouragingly, recent studies document several therapeutic successes of AAV-based gene 
therapy for genetic diseases in clinical trials [47–54,56–58], and Glybra, which involves the genetic 
delivery of lipoprotein lipase (LPL) by intramuscular injection of AAV1 vector to treat LPL deficiency 
disease, has just been licensed in Europe [55]. These successes ease some of the safety concerns and 
will certainly guide the clinical development of VIP. Finally, constitutive expression could induce 
immune responses against the VIP antibody and/or the F2A linker, which, in turn, could lead to 
reduced antibody production and other unknown effects. As a safety precaution, it might be desirable 
to develop a regulated expression system, such as the dimerizer-regulated gene expression  
system [116,122,123] to switch antibody expression on and off.  
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